阿帕替尼联合SOX方案治疗晚期胃癌合并顽固性癌性腹水患者的疗效分析

Curative Analysis of Apatinib Combined with SOX Scheme Treatment on Patients with Late Gastric Cancer Combined with Refractory Cancerous Ascites

分析阿帕替尼联合SOX方案治疗晚期胃癌合并顽固性癌性腹水患者的治疗效果。选取96例晚期胃癌合并顽固性癌性腹水患者为研究对象,分为对照组与观察组,每组各48例。观察组应用甲磺酸阿帕替尼片,对照组在观察组的基础上应用替吉奥胶囊联合SOX治疗。结果表明,对照组对晚期胃癌合并顽固性癌性腹水患者应用阿帕替尼+替吉奥+SOX方案进行干预,可取得满意效果,并缓解患者的不良反应。

The research analyzes the curative effect of apatinib combined with SOX scheme treatment on patients with late gastric cancer combined with refractory cancerous ascites.96 patients with late gastric cancer combined with refractory cancerous ascites are selected,and they are divided into control group and observation group,with 48 patients in each group.Apatinib mesylate tablets are applied in the observation group,and Tigeo capsule combined with SOX treatment is applied in the control group based on observation group.The results show that application of Apatinib+Tigeo+SOX scheme on patients with late gastric cancer combined with refractory cancerous ascites has achieved satisfactory effect,and relieved the adverse reaction of patients.